Sirona Biochem Announces Convertible Note Financing
VANCOUVER, BC–(Marketwired – January 31, 2017) – Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) announced today a non-brokered private placement (the “Private Placement”) of convertible notes (“Notes”) for gross proceeds of up to $600,000. Each Note will be convertible at the option of the holder into one common share of the company at a conversion price of $0.18 per share during the 18 month term of the Notes.
The Notes will mature in 18 months from the date of issuance and bear interest at the rate of 12{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} per annum, payable quarterly, until the Notes are converted or repaid. The company will be entitled to repay the principal amount of the Notes, together with accrued and unpaid interest, at any time commencing four months after the date of issuance, subject to giving the holders prior notice thereof to permit holders to convert during the notice period. The Notes are unsecured and transferable, subject to resale restrictions under applicable securities laws and TSX Venture Exchange requirements.
Sirona Biochem intends to use the net proceeds from the Private Placement for general working capital, and to support the company’s efforts to secure a licensing agreement for its skin lightening compound, TFC-1067. The company is expecting to receive a term sheet for a licensing transaction for TFC-1067 in Q1 2017 but there can be no assurances that a licensing agreement will be entered into on terms acceptable to Sirona Biochem or at all. The Company may pay fees of 7{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} in cash to qualified finders.
All securities issued in connection with the private placement will be subject to a statutory hold period of four months commencing from the date of issuance of the Notes. Closing of the private placement is subject to customary conditions, including TSX Venture Exchange acceptance.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.
In addition, the Company announces an extension to the term of 8,865,970 common share purchase warrants (the “Warrants”) originally issued on March 6, 2014. The warrants were issued as part of a private placement. The expiry dates will be extended as follows:
March 6, 2014
Number of Warrants: | 8,865,970 |
Original Expiry Date of Warrants: | March 6, 2017 |
New Expiry Date of Warrants: | April 30, 2017 |
Exercise Price of Warrants: | $0.20 |
All other terms of the Warrants will remain unchanged.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: a third party potential licensees of TFC-1067 may not deliver a term sheet to the company in Q1 2017 or at all; the company may not be able to negotiate a license agreement with a potential licensees of TFC-1067 on terms acceptable to Sirona Biochem; the progress and timing of its clinical trials are uncertain; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing products; unexpected adverse side effects or inadequate therapeutic efficacy of the company’s or licensed products that could delay or prevent product development or commercialization; the scope and validity of patent protection for the company’s or licensed products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
CONTACT INFORMATION
-
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Bio technology, News Home, Sirona Biochem
Sirona Biochem (SBM:tsxv) CEO’s Report on Progress
Sirona Biochem CEO’s Report on Progress
– Momentum Public Relations –
Press Release: December 8, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) today provided a business update.
Dear Shareholders,
The following is an update on our progress in 2016 and our plans for 2017.
Skin Lightener, TFC-1067
Throughout 2016, we have remained focused on completing a licensing agreement for our skin lightening compound, TFC-1067. It was our plan to finalize this transaction earlier in the year. However, it is not a timeline we have full control over. We have multiple companies engaged and progressing through due diligence at their own speed. Despite contrary market rumors, no party has left the negotiation table. At this time, we expect to receive one or more term sheets from interested parties before the end of Q4 2016. We remain very confident that one or more of these global entities will move forward with a definitive licensing agreement in early 2017.
Should the circumstances be that no potential licensing partner can complete the deal in a reasonable time frame, or for what we consider to be an appropriate value, then we will proceed with the full development of the skin lightener on our own. This would include GMP scale-up, toxicology, formulation and an early clinical trial. We already have consultants in France building the full development plan. We are aware that building a development plan may seem unnecessary but we take seriously our commitment to minimize risk and maximize opportunity for our shareholders. It is important that we are not dependent on a partner to complete a development plan and remain in a position of strength during negotiations.
SGLT2 Inhibitor, SBM-TFC-039 (Wanbang)
Wanbang Biopharmaceuticals recently provided a project update on the SGLT2 Inhibitor. We are very pleased to announce that they have completed most of the preclinical studies, the scale-up optimization and pharmaceutical grade manufacturing of the product. They will formulate the product in January 2017 to prepare for a clinical trial. Following that, they will conduct an additional pharmacology as well as toxicology study and file the “investigational new drug” (IND) package with the Chinese FDA (CFDA). This filing will trigger the next escalating milestone payment. Approval of the IND package by the CFDA will trigger another milestone payment and indicate the start of clinical studies.
The data that has been generated by Wanbang is currently being used in licensing discussions with a potential partner in India that recently approached us.
Skin Lightener, TFC-849 (Valeant) and Library
Our skin lightener, TFC-849 remains in scale-up at a French CRO for clinical studies. We did anticipate that this would be finalized earlier in 2016, however, the CRO experienced some complications and therefore it has been delayed until January. Valeant is aware of the delays in scale-up and has not altered plans to commercialize.
In 2016 we also completed the development of several other skin lighteners. This group contains potential lead compounds which can be licensed with TFC-1067 or separately in multiple markets. We have begun preliminary testing to determine the most effective new compounds, and expect results in Q1 2017.
Cell Preservation and Regenerative Compounds
We have now concluded testing of our glycoprotein compound library. We showed a protective effect in human fibroblasts (skin cells) under various stress conditions. Our subsidiary, TFChem has developed a comprehensive report of the data to be shared with potential partners. While the compounds have very interesting properties, they are still considered early stage, which means that the partnerships we seek will be considered “Research and Development” (R&D) collaborations. The compounds also have numerous potential applications and we need to take time to evaluate the best path to market. This is something we will advance with partner organizations.
One potential application is in storage of various cells and tissues. In May, we entered into a research program with Dr. Caigan Du’s laboratory (Vancouver Coastal Health Research Institute) on red blood cell storage and preservation. Results showed that while the compounds did not improve total blood cell count, they did improve the health of the cells that survived. This could result in more cells remaining viable in transfusions (where many typically die). Testing in commercial storage protocols will begin in 2017.
Dr. Du also carried out a study on oxidative stress in skin cells. The results confirmed what our previous CROs have found, which is a significant preservation under stress conditions. This data is currently being compiled and will be used for partnering discussions.
Acne Compound
Our acne compound is in chemistry development and expected to be completed and ready for testing in mid-2017. It will likely be our next major pipeline candidate. This project utilizes our successful business model of applying our proprietary technology to a known compound with stability issues. There is an excellent opportunity to produce a new therapy in this market which is estimated to be $8 Billion USD worldwide annually. Acne is the most common skin condition in the United States affecting some 50 million Americans and costing $3 Billion USD annually.
Keloid
We have developed a compound that we believe could have properties in preventing the formation of keloid scars. This is a significant unmet need as there are currently no effective therapies available. Early In vitro studies show a down-regulation of genes involved in the Extracellular Matrix (ECM) deposit which occurs in keloid scars and an up-regulation of genes involved in ECM degradation. Early safety tests have also been completed.
We have also uncovered mechanisms of action favourable to the target therapy and started to build a development plan for this project. Moreover, we are exploring CRO’s and universities in Europe with expertise in keloid research to assist us. The current market for global scar therapy is estimated at $16 Billion USD annually.
Like all biotech companies, we have experienced some delays in the development of our pipeline. We understand the apprehension that this can create for our investors and we want to assure you that we have a strong technology platform, a strong development pipeline, excellent patent protection and a dedicated management team. We are doing everything we can to sustainably increase shareholder value. We thank you for your continued support and look forward to what 2017 will bring.
Wishing you and your families Happy Holidays and all the best for 2017.
Sincerely,
Dr. Howard Verrico, CEO
- Published in News Home, Sirona Biochem
The Holy Grail of Skin Whitening Products – Expert Panel Discussion with Sirona Biochem
Sirona Biochem – The Holy Grail of Skin Whitening Products
– Momentum Public Relations –
September 22, 2016
Sirona Biochem (SBM:tsxv) is a proactive development and discovery stage based biotech firm with an R&D lab situated in Paris, France. The biotechnology enterprise is headquartered in Vancouver, British Columbia in Canada, and is world renowned for its state of the art fluorination chemistry technology. Their cutting edge platform is currently used to create cosmetic products that are both safe and effective for human use and consumption, as well as a plethora of pharmaceutical drugs.
Moreover, their leading edge compounds are either acquired by or licensed by multinational conglomerates in return for royalties, milestone payments, and/or marked upfront payments. It should also be noted that their platform focuses on the molecular stabilization of carbohydrates; which is noteworthy because carbohydrate based drugs are one of the most commonly prescribed drug families in the United States.
Notably, Sirona is currently working on what would be a company changing deal to license their newest compound, ‘Skin Lightener SBM-TFC-1067’. Globally, there is a growing trend for lighter skin in many parts of the world. Approximately 15{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of the world population invests in skin lightening products and the global market is expected to reach US$23 billion by 2020. Below is an excerpt from a recent CEO update explaining how they have a product that has garnered them serious interest from some of the world’s largest cosmetic / pharmaceutical companies.
Skin Lightener SBM-TFC-1067
SBM-TFC-1067 continues to attract the interest of global cosmetic companies, a list which continues to grow. A number of these companies completed material transfer agreements allowing them to test the compound in their facilities. We successfully scaled-up and produced over 1 kg of compound. In parallel, we completed independent testing in a 3D melanocyte model that mimics human skin. The results showed a strong skin lightener at low dosing without signs of toxicity. As this model is used by our potential partners to assess compounds, the study was key to obtaining independent results and improving our negotiating position. (view full CEO Update)
In addition, Sirona Biochem currently has two licensing agreements with two multi-billion dollar companies; namely Valeant Pharmaceuticals International (VRX:tsx) and Wanbang Biopharma.
The Annual General Meeting (AGM) was held yesterday in Vancouver, BC. Investors were clearly happy with what they heard. The stock price traded up on good volume. Management was very enthusiastic and are confident in their negotiations to secure a licensing deal with a global corporation for the Skin Lightening compound. For understandable reasons Management could not disclose details of their private discussions with the interested purchaser(s), however, the general consensus with investors is that Sirona (SBM:tsxv) is a Buy or at least a very enthusiastic hold.
The video below which was recently released will give you an in-depth look at this market and Sirona’s role in it. Spoiler Alert: First Berlin analyst Ellis Acklin explains their current price target of 98 cents for SBM. That’s a price target that excludes the potential SBM-TFC-1067 licensing deal. Keep in mind that as of today Sirona is only trading at 20 cents CND.
The Holy Grail of Skin Whitening Products – Expert Panel Discussion with Sirona Biochem
This message does not constitute investment advice. Momentum PR provides this material for convenience and information purposes only.
- Published in Bio technology, Blog, Sirona Biochem
Cell Preservation Research – A New Frontier
CELL PRESERVATION RESEARCH – A NEW FRONTIER
– Momentum Public Relations –
“The planet’s hope and salvation lies in the adoption of revolutionary new knowledge being revealed at the frontiers of science” – Bruce Lipton
Although Dr. Lipton may not be universally revered in mainstream science, his comment is noteworthy. Medical science and technology continue to break new ground. New compounds and techniques are in the testing stage that offer promising treatments to address a variety of life threatening conditions.
Investors are noticing. Investment, specifically in cell preservation research, is growing very rapidly. New breakthroughs are demonstrating that cell storage is achievable in the near term. Advances in cell preservation compounds coupled with new storage protocols have the potential to vastly improve treatment protocols and, ultimately, outcomes for a variety of diseases.
David Juncker, an expert in high-throughput cell analysis from McGill University, in Montreal, Canada, has stated that “cell preservation and manipulation is of great interest”. While it has many variations, cell preservation can be useful in areas as diverse as stem cell storage, reproductive science, transplants, treatment of various cancers and the storage of blood products.
Recently, Sirona Biochem Corporation (SBM:tsxv), a development-stage biotechnology company with a market cap of C$29.4 million has entered into a research collaboration with Dr. Caigan Du. http://www.vchri.ca/researchers/caigan-du
The collaboration between Sirona and Dr. Du will evaluate and test the effects of new compounds, produced by Sirona’s subsidiary TFChem, for use in the preservation of red blood cells. Scientists will evaluate the potential for improvement in the quality of red blood cells after hypothermic storage and cryopreservation. Eventually, testing will begin on other cell lines with further research related to tissue preservation for applications such as organ transplant. The initial testing will begin in May with results expected in fourth quarter 2016.
Current typical storage of donated blood is limited to approximately 42 days. If scientists can successfully design a process that prevents the degradation or spoilage of blood products it will have the potential to save lives at times of disaster. It will also allow blood banks to maintain a supply of rare blood types and lessen overall blood inventory losses. Scientists concur that there is a global unmet need when it comes to storage and shelf life of blood products. A process that extends the shelf life would significantly improve the ability to use donated blood.
The use of preservation techniques, both cryopreservation and hypothermic storage, is already widespread both in laboratory and clinical settings. The challenge has been that the specific protocols and process utilized for preserving cells have specific limitations. As such, they tend to provide suboptimal results and often do not incorporate modern day preservation media, which can offer significant improvements over serum/DMSO cocktails. Additionally, many of the techniques commonly applied to assess cryopreservation success are inferior based on modern day standards.
Frontiers are expanding as further research into areas like tissue preservation for applications such as organ transplant is showing promising results. Most experts agree that one of the important keys to success is in the discovery and refinement of the compounds and media that are a limiting factor in current cell preservation processes. Investors should evaluate the various emerging opportunities to take positions in firms that are leading the way.
- Published in Blog, Life Sciences, Sirona Biochem
Sirona Biochem (SBM:tsxv) CEO’s Report on Progress
Sirona Biochem CEO’s Report on Progress
– Momentum Public Relations – June 30, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) today provided a business update.
Dear Shareholders,
I would like to provide an update on our progress.
As we enter Q3, our resources continue to be focused on completing a license agreement for our skin lightener SBM-TFC-1067 with a global cosmetic company. While we initially anticipated a deal by the end of Q2, these types of agreements take time and we appreciate your patience. We are very confident in our ability to secure a licensing deal for SBM-TFC-1067.
Skin Lightener SBM-TFC-1067
SBM-TFC-1067 continues to attract the interest of global cosmetic companies, a list which continues to grow. A number of these companies completed material transfer agreements allowing them to test the compound in their facilities. We successfully scaled-up and produced over 1 kg of compound. In parallel, we completed independent testing in a 3D melanocyte model that mimics human skin. The results showed a strong skin lightener at low dosing without signs of toxicity. As this model is used by our potential partners to assess compounds, the study was key to obtaining independent results and improving our negotiating position.
Anti-Aging and Regenerative Compounds
We advanced our anti-aging and regenerative-medicine project by adding several compounds to our library which now consists of 16 novel compounds. With our lead compounds, we were able to show a protective effect in human fibroblast studies under stress conditions. Several global corporations have expressed interest and have signed material transfer agreements. These companies have been provided material for testing.
SGLT2 Inhibitor SBM-TFC-039
Wanbang Biopharmaceuticals has moved into pre-IND (Investigational New Drug) studies with SBM-TFC-039 for type 2 diabetes in China. Upon completion, Wanbang will file the IND with the CFDA. A successful filing will result in a $500,000 USD milestone payment for Sirona. We continue to work with Wanbang and provide technical support for the ongoing studies.
The company continues to maintain a healthy balance sheet and recently generated $829,500 as a result of a non-brokered private placement.
Looking back, over the last 12 months, Sirona Biochem has completed the following:
- Advanced discussions for a licensing deal for SBM-TFC-1067.
- Completed testing in a 3-D melanocyte skin model with excellent results.
- Obtained a milestone payment of $300,000 USD from Wanbang Biopharmaceuticals.
- Advanced the Obagi skin-lightening project.
- Increased the anti-aging and cell preservation library of compounds.
- Entered into material transfer agreements with various global companies for testing of the anti-aging/cell preservation library.
- Launched programs for Keloid scar and acne therapies.
- Launched a red blood cell preservation program.
- Presented at multiple global conferences with a focus on cosmetic ingredients.
Thank you for your continued support. Management remains confident that 2016 will be transformational for Sirona Biochem.
Sincerely,
Dr. Howard Verrico, CEO
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information visit www.sironabiochem.com.
- Published in Life Sciences, News Home, Sirona Biochem
Sirona Biochem Announces Positive Safety and Efficacy Data for Innovative Skin Lightening Compound
Sirona Biochem Announces Positive Safety and Efficacy Data for Innovative Skin Lightening Compound SBM-TFC-1067 Accepted as Abstract Presentation by IMCAS
– Momentum Public Relations – June 16th, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announced positive preclinical safety and efficacy data with SBM-TFC-1067 in a 3-D human skin-like model was accepted as an abstract for oral presentation by Sirona’s Chief Scientific Officer, Geraldine Deliencourt-Godefroy, at the IMCAS Asia Conference in Taipei on July 31, 2016.
Sirona has now demonstrated significant skin lightening in a model used by cosmetic scientists and leading cosmetic corporations around the world. In the study, SBM-TFC-1067, was topically applied daily to a MatTek Corps Melanoderm 3-D human skin model for 14 days using 3 different concentrations (0.1, 0.05 and 0.01{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}). Pigmentation was evaluated on days 0, 7, 11, and 14 using a chromameter to measure brightness (L*D65). Total melanin content was quantified after day 14. Results showed a statistically significant difference in surface reflectance with the 0.1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} and 0.05{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} concentrations of 1067. There was also a significant reduction of melanin quantity, which translates to visibly lighter skin.
The full abstract can be viewed on the IMCAS website here: http://www.imcas.com/en/attend/imcas-asia-2016/program/session/6150
“This is definitely good news for the millions of individuals around the world with hyperpigmentation or melasma”, said Attila Hajdu, Chief Business Development Officer of Sirona Biochem. “This exciting new data shows significant reduction in pigmentation without toxicity in human skin and being accepted as an abstract in the clinical dermatology stream at IMCAS is scientific validation.”
About IMCAS
Since its inception a decade ago, IMCAS has become one of the most important international programs dedicated to skin treatments. IMCAS Asia 2016, will bring together practitioners from across the Asia-Pacific region for informative and engaging exchanges. Over 2000 attendees and 80 exhibiting companies will come together for three days of intense learning in Taipei. Large cosmetic company representatives will also be in attendance to learn about the most innovative advances in the dermatology industry.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
About the Skin Lightening Project
Sirona Biochem’s French subsidiary TFChem received a $1.9 million grant in November 2011. This project is co-financed by the European Union and Europe Witnesses in Haute-Normandie with the support of the European Regional Development Fund (E.R.D.F.). A consortium of partners, including the University of Rouen (LMSM EA4312), contract research organization Biogalenys, and TFChem has been assembled to advance this project. The French government and EU are looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation.
- Published in Business, Life Sciences, News Home, Sirona Biochem
Sirona (SBM:tsxv) Announces Wanbang to Proceed with Pre-IND and Milestone Payment
Sirona Biochem Announces Wanbang Biopharmaceuticals to Proceed to Pre-IND Testing and Receipt of $300,000 USD Milestone Payment
– Momentum Public Relations – June 13th, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) today announced that Wanbang Biopharmaceuticals has confirmed they will be proceeding with studies to prepare for Investigational New Drug (IND) filing for the anti-diabetic SGLT2 Inhibitor, SBM-TFC-039. IND filing and approval is required to proceed to clinical testing. Sirona Biochem has received a milestone payment of US$ 300,000 from Wanbang Biopharmaceuticals.
The set of studies, which will comprise of CMC (chemistry manufacturing and controls), sample preparation and any additional toxicology and pharmacokinetic studies, will be in accordance with the China Food and Drug Administration for enabling IND filing. Successful IND filing will result in a US$ 500,000 payment to Sirona Biochem as part of the US$ 9.5M in upfront and milestone payments according to the license contract with Wanbang Biopharmaceuticals.
“Based on promising results in our first set of studies, we will move the drug to the next phase and prepare for clinic trials,” said Ning Yuan, Vice President Business Development at Wanbang Biopharmaceuticals. “We are very pleased with the results and the productive collaboration with Sirona Biochem.”
“The advancement into pre-IND means that our partner is close to moving into the clinic with our SGLT2 inhibitor,” said Dr. Howard Verrico, CEO of Sirona Biochem. “This next step represents a significant achievement on this project as we continue toward commercialization in China and strengthen our negotiation position on global partnering. We look forward to continued success.”
About Wanbang Biopharmaceuticals
Wanbang Biopharmaceuticals is the leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Biopharmaceuticals is one of the largest manufacturers and marketers of a comprehensive portfolio of drugs for diabetes.
Wanbang Biopharmaceuticals is a subsidiary of Shanghai Pharmaceutical Group which is listed on the Shanghai Stock Exchange.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
- Published in Business, Life Sciences, News Home, Sirona Biochem
Sirona Biochem to Present New Test Results of SBM-TFC-1067 at Global Conferences
Sirona Biochem to Present New Test Results of SBM-TFC-1067 at Global Conferences
– Momentum Public Relations – May 17, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) is pleased to announce participation, in the form of presentations and exhibitions, in several global cosmetic industry conferences.
“Maintaining a strong presence in the global cosmetic industry is important as we continue to grow our pipeline and explore new areas of dermatology,” explained Attila Hajdu, Chief Business Development Officer of Sirona Biochem. “These conferences provide a great opportunity to conduct business with the key players in the industry in a timely and efficient manner.”
May 18-20: Attila Hajdu, Chief Business Development Officer of Sirona Biochem, will be exhibiting at China Beauty Expo in Shanghai and attending other business meetings in China and Korea. For more information on this conference, please visit: www.chinabeautyexpo.com/en
May 24-25: Dr. Geraldine Deliencourt-Godefroy, Chief Scientific Officer of Sirona Biochem, will present at COSM’innov 2016, the international congress on cosmetic science in Orléans France. CSOM’innov is where academia meets business as leading organizations seek the latest advances in the science of cosmetology. For more information on this conference, please visit: www.cosminnov.com
June 9-10: Attila Hajdu, Chief Business Development Officer of Sirona Biochem, will be presenting at the Innocos World Beauty Innovation Summit in Vienna, Austria. As a Gold Sponsor of the event, Sirona will have VIP access and dedicated 1:1 business meetings with senior executives from leading companies such as: Amore Pacific, Amway, Beiersdorf, Yves Rocher, Mirai Clinical, Sisley and Unilever. For more information on this conference, please visit: www.innocossummit.com
“As part of due diligence of a third party, our CRO performed additional safety and efficacy studies with our innovative skin lightening compound SBM-TFC-1067 in the last several weeks. The results are a major milestone that will significantly help us to close a licensing deal for this new compound in due course. Furthermore, it will provide scientific credibility enabling potential partners to initiate formulation and clinical trials required for approval of SBM-TFC-1067 in the major markets of the world (Japan, Korea, China, Europe and North America),” said Dr. Howard Verrico, CEO of Sirona Biochem.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant.
For more information please visit www.sironabiochem.com
- Published in Blog, News Home, Sirona Biochem
Sirona Biochem (SBM.V) Announces Close of Financing
Sirona Biochem Announces Close of Financing
– Momentum Public Relations – May 11, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) is pleased to announce that it has closed a private placement in the amount of 4,147,500 units at $0.20 per unit for total gross proceeds of $829,500. Each unit consists of one common share and one-half of one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of two years from the date of issue at a price of $0.30 per share.
The Company paid a total of $24,000 in finder’s fees in connection with the placement.
All securities issued under the placement are subject to statutory hold periods expiring on September 12, 2016.
Proceeds of the placement will be used for research and development purposes and for general working capital.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information please visit www.sironabiochem.com.
- Published in News Home, Sirona Biochem
Sirona Biochem (SBM.V) Initiates Research and Development on New Therapies
Sirona Biochem Initiates Research and Development on New Therapies for Keloid Scars and Acne Vulgar
– Momentum Public Relations – April 18, 2016
Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB) (the “Company“) announces that its CEO, Dr. Howard Verrico, has approved two new therapeutic projects within the skin care portfolio addressing markets with unmet needs. Research and development will proceed for a novel compound for keloid scars and an acne treatment, each with a potentially favourable efficacy/side-effect-profile. Studies have begun for the keloid scar project with initial results expected in Q4 2016. The development program is being established for the acne program and will commence this quarter. The Company will look to partner the therapeutics after In-Vitro studies.
A keloid scar is an overgrown scar that can spread outside the original area of skin damage. Keloid scars are raised above the surrounding skin, and can feel hard and rubbery. Keloids affect around 10-15{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of all wounds. Current treatments for Keloids have very limited results leaving a large unmet need. According to a report recently published by Persistence Market Research (PMR), the global scar treatment market is poised to rise at a CAGR of 10.3{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} from US$ 16.0 Billion in 2015 to over US$ 31.9 Billion by 2022. Some of the key players in the keloid treatment market are Novartis, GlaxoSmithKline, Galena Biopharma, Bristol-Myers Squibb and Valeant Pharmaceuticals International.
Recent testing of compounds created by Sirona’s wholly-owned French subsidiary, TFChem, has shown properties suggesting potential application in the treatment of Keloids. Further testing is underway and a detailed project plan is being developed.
Acne vulgar is a long lasting skin disease that occurs when dead skin cells and oil from the skin become clogged with hair follicles or skin pores. Severe acne is inflammatory, but acne can also manifest in non-inflammatory forms. Acne affects the majority of the world’s population and there is an unmet need with current therapies. The global acne market is estimated to reach US$ 4.4 Billion by 2020 (Technavio, 2016). Some of the key players in the acne vulgaris treatment market include Galderma, Allergan, Bayer, Cipher, Johnson & Johnson and Valeant Pharmaceutical International.
“In anticipation of a near-term upfront payment as part of a licensing agreement for our novel skin lightening compound, we are increasing our research activities substantially,” reports Dr. Howard Verrico, Chairman and CEO of Sirona Biochem.
“Dr. Geraldine Deliencourt-Godefroy, our Chief Scientific Officer, has identified promising compounds using our innovative carbohydrate fluorination technology. Although at an early stage in development, our scientific team has an excellent track record of predicting how the fluorination process improves carbohydrate cosmetic and therapeutic agents,” he added.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant.
For more information, please visit www.sironabiochem.com.
- Published in Blog, Life Sciences, News Home, Sirona Biochem